BioTime Aktie

0,3460 EUR +0,0100 EUR +2,98 %

08.04.2025

STU

0,3862 USD -0,0161 USD -4,00 %

08.04.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.83,19 Mio. EUR

Div. Rendite0,00%

WKNA2PP89

ISINUS53566P1093

SymbolLCTX

BioTime Aktien News

Sortieren:Datum Meistgelesen

10.08.23BusinesswireLineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

03.08.23BusinesswireLineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

24.07.23BusinesswireLineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

22.05.23BusinesswireLineage Cell Therapeutics Expected to Be Added to Russell 3000® Index

11.05.23BusinesswireLineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

09.05.23BusinesswireLineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

04.05.23BusinesswireLineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

26.04.23BusinesswireRG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

18.04.23BusinesswireLineage to Present at 2023 AAPS National Biotechnology Conference

30.03.23BusinesswireLineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium

20.03.23BusinesswireRG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

09.03.23BusinesswireLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

06.03.23BusinesswireRG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.

02.03.23BusinesswireLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023

22.02.23BusinesswireLineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

08.02.23BusinesswireLineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss

29.11.22BusinesswireLineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

28.11.22BusinesswireLineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

10.11.22BusinesswireLineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

03.11.22BusinesswireLineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022

31.10.22BusinesswireLineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

10.10.22BusinesswireLineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells

04.10.22BusinesswireLineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa

03.10.22BusinesswireLineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel

15.08.22BusinesswireLineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference

11.08.22BusinesswireLineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

04.08.22BusinesswireLineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022

02.06.22BusinesswireLineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology

12.05.22BusinesswireLineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

05.05.22BusinesswireLineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022

03.05.22BusinesswireRG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

26.04.22BusinesswireLineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

25.04.22BusinesswireLineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

13.04.22BusinesswireLineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

11.04.22BusinesswireLineage to Present at the NobleCon18 Investor Conference on April 20, 2022

BioTime News

BioTime News: auf dieser Seite finden Sie alle BioTime News und Nachrichten zur BioTime Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch BioTime News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um BioTime News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.